Trademark Overview
On Wednesday, May 22, 2024, a trademark application was filed for GENUITI with the United States Patent and Trademark Office. The USPTO has given the GENUITI trademark a serial number of 98562943. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Monday, June 16, 2025. This trademark is owned by GENUITI THERAPEUTICS, INC.. The GENUITI trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
therapeutic pharmaceuticals for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical products for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical preparations for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceuticals comprising small molecules for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; none of the foregoing for use related to DNA or RNA screening or analysis services or software
scientific research for medical purposes in the fields of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development of therapeutics for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development in the field of small molecule drug discovery; medical and scientific research in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical products development in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; drug discovery services in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical research and development services in the field of obesity and metabolic diseas...
